Abstract
Chemical modulation of a formerly disclosed DGAT-1 inhibitor resulted in the identification of a compound with a suitable profile for preclinical development. Optimisation of solubility is discussed and a PK/PD study is presented.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have